tbuckley/cabot-search huggingface dataset:
Isoform-specific silencing of WNK1-4 points to shared functions in promotion of contraction and growth of prostate stromal cells, which are inhibited by the WNK inhibitor, WNK463
Authors: Y. Liu, R. Wang, R. Huang, A. Tamalunas, R. Waidelich, F. Strittmatter, C.G. Stief, M. Hennenberg
Journal: European Urology (2023)
Prostate cancer detection rate of repeated biopsy in patients with positive mpMRI and negative initial target and random biopsy. An EAU-YAU Prostate Cancer Working Group multi-institutional study
Authors: F. Zattoni, L.J.P. Pereira, J. Zhuang, J. Olivier, I. Puche-Sanz, P. Rajwa, G. La Bombarda, M. Maggi, A. Fuschi, A. Veccia, F. Ditonno, G. Marra, M. Valerio, V. Kasivisvanathan, A. Alessandro, F. Dal Moro, J.G. Rivas, R. Van Den Bergh, G. Gandaglia, G. Novara
Journal: European Urology (2023)
Developmental origins of Parkinson disease: Improving the rodent models
Authors: Irene Jiménez-Salvador, Patricia Meade, Eldris Iglesias, Pilar Bayona-Bafaluy, Eduardo Ruiz-Pesini
Journal: Ageing Research Reviews (2023)

Numerous pesticides are inhibitors of the oxidative phosphorylation system. Oxidative phosphorylation dysfunction adversely affects neurogenesis and often accompanies Parkinson disease. Since brain development occurs mainly in the prenatal period, early exposure to pesticides could alter the development of the nervous system and increase the risk of Parkinson disease. Different rodent models have been used to confirm this hypothesis. However, more precise considerations of the selected strain, the xenobiotic, its mode of administration, and the timing of animal analysis, are necessary to resemble the model to the human clinical condition and obtain more reliable results.
Retzius-sparing robot-assisted radical prostatectomy after previous trans-urethral resection of the prostate: Assessment of functional and oncological outcomes
Authors: S. Tappero, E. Vecchio, E. Palagonia, G. Granelli, M. Martiriggiano, O. Maltzman, A. Olivero, S. Secco, A.M. Bocciardi, A. Galfano, P. Dell’Oglio
Journal: European Urology (2023)
Partial vs. radical nephrectomy to treat pT3a renal cancers: Propensity score matched analysis of a single center series
Authors: A. Brassetti, U. Anceschi, A.M. Bove, S. Cartolano, M. Costantini, M.C. Ferriero, R. Mastroianni, L. Misuraca, G. Tuderti, G. Simone
Journal: European Urology (2023)
Pathophysiological analysis of detrusor overactivity following partial bladder outlet obstruction
Authors: H. Morinaka, S. Ohira, S. Tone, S. Kakumae, T. Nakatsuka, H. Takasaki, K. Hirata, S. Shimizu, M. Kaifu, T. Fujii, Y. Miyaji
Journal: European Urology (2023)
A Novel Clinical Prostate Score (CLIPS) for Minimally Invasive Therapy (MIST) of Prostate
Authors: W.C. Tsang, A.J.Y. Quek, T.Y.X Law, X.W.G. Pek, S.M. Tham, W.J. Chua, D.T. Consigliere
Journal: European Urology (2023)
Rejected living kidney donors due to nephrolithiasis. Does it really matter?
Authors: A. Sierra, E. Carbonell, C. Martinez, M. Muní, J.M. López, M.P. Luque, S. Olivella, I. Revuelta, F. Diekmann, L. Peri, A. Alcaraz, M. Musquera
Journal: European Urology (2023)
Lymphovascular invasion predicts lymph node involvement in patients with renal cell carcinoma
Authors: C. Re, F. Belladelli, F. Cei, T. Nazario, G. Basile, G. Musso, G. Fallara, G. Rosiello, R. Matloob, M. Moschini, D. Cignoli, D. Canibus, P.I. Karakiewicz, I. Rowe, R. Lucianò, C. Doglioni, M. Colecchia, R. Bertini, A. Briganti, F. Montorsi, A. Salonia, A. Larcher, U. Capitanio
Journal: European Urology (2023)
Incidental prostate cancer in MRI era. Is there a need for expansion in guidelines?
Authors: F.E. Esperto, L. Cacciatore, A. Minore, G.R. Raso, A.T. Testa, N.D. Deanesi, F.T. Tedesco, R.P. Papalia, R.M.S. Scarpa
Journal: European Urology (2023)
Is today still necessary to perform a repeated transurethral resection of the bladder after hexaminolévulinate photodynamic diagnosis-assisted TURB?
Authors: V. Lorusso, G. Pignot, L. Doisy, A. Pacchetti, C. Rion, A. Le Quellec, F. Lannes, D. Sypre, N. Branger, M. Thomas, S. Rybikowski, J. Walz
Journal: European Urology (2023)
En bloc resection versus conventional TURBT for T1HG bladder cancer: A propensity score-matched analysis
Authors: T. Yanagiswawa, A. Matsukawa, K. Iwatani, S. Sato, Y. Hayashida, Y. Okada, T. Yorozu, W. Fukuokaya, K. Sakanaka, F. Urabe, S. Kimura, S. Tsuzuki, M. Shimoda, H. Takahashi, J. Miki, S.F. Shariat, T. Kimura
Journal: European Urology (2023)
Impact of pre-operative PSMA PET/CT for men with cN0M0 conventional imaging and pN+ prostate cancer: Results from a multicenter study
Authors: G. Marra, P. Rajwa, G. Montefusco, R.C.N. Van Den Bergh, F. Zattoni, F. Dal Moro, A. Magli, A. Affentranger, J.B. Grogg, T. Hermanns, B. Malkiewicz, K. Kowalczyk, S. Shariat, A. Bianchi, A. Antonelli, S. Gallina, W. Berchiche, X. Cathelineau, L. Afferi, C. Fankhauser, A. Mattei, S. Scuderi, A. Briganti, P. Gontero, G. Gandaglia
Journal: European Urology (2023)
PRIMETEST II – trial to test new predictors of recurrence in CS II A/B seminoma patients treated with primary robot-assisted retroperitoneal lymph node dissection
Authors: Y. Che, T. Zuiverloon, A. Arnout, M. Vermeulen, P. Pongratanakul, D. Nettersheim, G. Niegisch, P. Albers
Journal: European Urology (2023)
Virtue sub-urethral sling for stress urinary incontinence after radical prostatectomy: A single-center experience
Authors: E. Beatrici, S. Scarcella, C. Del Prete, G. Giglioni, S. Cappuccelli, L. Pitoni, G. Gabrielloni, V. Lacetera, V. Beatrici
Journal: European Urology (2023)
On-treatment modified Glasgow prognostic score (mGPS) improves imaging-only prediction of response and outcomes in metastatic renal cell carcinoma
Authors: J. Saal, T. Bald, M. Eckstein, D.J. Ralser, M. Ritter, P. Brossart, V. Grünwald, M. Hölzel, J. Ellinger, N. Klümper
Journal: European Urology (2023)
Can we avoid second transurethral resection according to VI-RADS score in patients with high-risk non-muscle-invasive bladder cancer?
Authors: Y. Nakamura, S. Yoshida, Y. Arita, R. Takeshita, K. Kimura, Y. Aida, S. Asai, Y. Maezawa, K. Yoshitomi, W. Chen, T. Soma, M. Kobayashi, M. Fujiwara, B. Fan, Y. Ishikawa, S. Fukuda, Y. Waseda, H. Tanaka, M. Yokoyama, M. Jinzaki, Y. Fujii
Journal: European Urology (2023)
Defining the most useful intermediate endpoint for overall survival in intermediate and high-risk clear cell carcinoma
Authors: G. Fallara, A. Martini, G. Rosiello, F. Belladelli, G. Musso, F. Cei, G. Basile, C. Re, D. Cignoli, F. De Cobelli, G. Brembilla, L. Marandino, D. Raggi, G. Gandaglia, E. Mazzone, M. Moschini, A. Stabile, A. Briganti, A. Necchi, F. Montorsi, A. Salonia, A. Larcher, U. Capitanio
Journal: European Urology (2023)
Molecular superglue-mediated higher-order assembly of TRAIL variants with superior apoptosis induction and antitumor activity
Authors: Hao Yang, Heng Li, Fen Yang, Ze Tao, Qiuxiao Shi, Tianshan She, Yanru Feng, Zhao Li, Jie Chen, Yi Zhong, Tao Su, Wengjuan Zeng, Yong Zhang, Shisheng Wang, Lan Li, Tingting Long, Dan Long, Jingqiu Cheng, Hong Zhu, Xiaofeng Lu
Journal: Biomaterials (2023)
Prognostic value of fat loss in patients with metastatic clear cell renal cell carcinoma treated with immune checkpoint inhibition
Authors: J. Lee, S.M. Lee, J.H. Lee, S. Hwang, B. Jee, J. Kim, J.H. Chung, W. Song, H.H. Sung, H.G. Jeon, B.C. Jeong, S.I. Seo, S.S. Jeon, H.M. Lee, S.H. Park, G.Y. Kwon, M. Kang
Journal: European Urology (2023)
mpMRI of the prostate in patients carrying a high clinical risk of prostate cancer diagnosis: Is this imaging test necessary for diagnostic purposes in this subset of patients?
Authors: A. Stabile, G. Gandaglia, F. Pellegrino, L. Afferi, J. Zhuang, H. Guo, P. Gontero, A. Minervini, G. Ploussard, E. Mazzone, M. Valerio, V. Cucchiara, N. Fossati, M. Moschini, A. Mattei, S. Serni, R. Rahota, J.B. Beauval, A. Marquis, A. Rakauskas, R. Van Den Bergh, T. Soeterik, F. Montorsi, A. Briganti
Journal: European Urology (2023)
Trends in radiation protection use and radiation exposure of European endourologists: an ESUT-YAU Endourology Group prospective trial
Authors: A.C. Bravo Balado, S. Fontanet, A. Skolarikos, A.S. Gozen, B.K. Somani, O. Traxer, A. Papatsoris, A. Ruiz Martínez, M. Talso, L. Villa, A. Pietropaolo, S. Tonyali, E.X. Keller, T. Tailly, P. Kallidonis, E. Sener, U. Nagele, V. De Coninck, F. Esperto, B.Z. Hameed, A. Kanashiro, O. Angerri, E. Emiliani
Journal: European Urology (2023)
Urodynamic predictors of daytime and night-time urinary incontinence for Florin and Padua intracorporeal robotic neobladders: Results from two tertiary-care centres at a mid-term follow-up
Authors: U. Anceschi, F. Di Maida, L. Lambertini, F. Prata, C. Fede Spicchiale, M. Mattioli, A. Cadenar, A. Brassetti, S. Nardoni, G. Tuderti, F. Valastro, M.C. Ferriero, M. Bacchiani, R. Mastroianni, A. Iannuzzi, A. Ragusa, V. Salamone, A.A. Grosso, A. Mari, A. Tuccio, E. Finazzi Agrò, C. De Nunzio, A. Minervini, G. Simone
Journal: European Urology (2023)
Is there an impact of transperineal vs. transrectal MRI-targeted biopsy on the risk of upgrading and concordance with final pathology in prostate cancer patients undergoing radical prostatectomy? An EAU-YAU study
Authors: F. Zattoni, G. Marra, A. Martini, V. Kasivisvanathan, J. Grummet, T. Harkin, G. Ploussard, J. Olivier, P.K. Chiu, M. Valerio, A. Marquis, P. Gontero, H. Guo, J. Zhuang, M. Frydenberg, D. Moon, A. Kretschmer, I. Heidegger, D. Tilki, R. Van Den Bergh, G. Novara, F. Dal Moro, A. Briganti, G. Gandaglia, Giorgio Gandaglia
Journal: European Urology (2023)
Data users must observe all principles of Data Protection Act
Authors: P. J Jones
Journal: BMJ (1996)

EDITOR,—Craig Gerrand's letter raises important questions. Health professionals who hold log books or do clinical research that entails holding personal data on computer must ensure this is covered by an appropriate registration under the Data Protection Act 1984. Health professionals maintaining computerised records relating to treatment they have provided as employees of a trust will be covered by a registration held by the trust as data user (section 1(5) of the act). When they hold personal data in connection with …
Do all patients equally benefit from the Enhanced Recovery After Surgery (ERAS) protocol after radical cystectomy?
Authors: G. Basile, R. Leni, C. Re, F. Pellegrino, G. Avesani, P. Scilipoti, M. Longoni, D. Cannoletta, G. Gandaglia, A. Necchi, A. Salonia, A. Briganti, F. Montorsi, M. Moschini
Journal: European Urology (2023)
Utilization of telemedicine in cancer patients: An analysis of the National Health Interview Survey Data in the Covid-19 era
Authors: K. Alkhatib, Z.J. Qian, C. Gu, B.V. Stone, M. Koelker, M. Labban, N. Frego, P.M. Pierorazio, A.P. Cole, Q-D. Trinh
Journal: European Urology (2023)
Enhancing bacteriophage therapeutics through in situ production and release of heterologous antimicrobial effectors
Authors: L. Leitner, J. Du, S. Meile, J. Baggenstos, T. Jäggi, P. Piffaretti, L. Hunold, C.I. Matter, T.M. Kessler, M.J. Loesser, S. Kilcher, M. Dunne
Journal: European Urology (2023)
The additional effect of the sperm DNA fragmentation index to predict pregnancy in primary infertile couple undergoing medically assisted reproduction
Authors: G. Fallara, P. Capogrosso, E. Pozzi, F. Belladelli, S. Cilio, M. Raffo, F. Negri, L. Cella, M. Fantin, F. Lanzaro, A. Bertini, L. Boeri, C. Corsini, L. Candela, A. D’Arma, L. Pagliardini, F. Dehò, F. Montorsi, A. Salonia
Journal: European Urology (2023)
The value of urinary based rapid tests during follow-up in bladder cancer: BTA stat®, Alere NMP22® BladderChek®, UBC® rapid test, CancerCheck® UBC® rapid VISUAL, and uromonitor® in comparison to cytology
Authors: T.H. Ecke, C.J. Meisl, S. Hofbauer, F. Labonté, T. Schlomm, D. Rong, A. Rabien, F. Friedersdorff, L. Sommerfeldt, N. Gagel, A. Gössl, D. Barski, T. Otto, C.M. Grunewald, G. Niegisch, M.J.P. Hennig, M.W. Kramer, M. Waldner, S. Koch, S. Hallmann, E. Veltrup, F. Linden, R. Wirtz
Journal: European Urology (2023)
Time for Double-J (DJ) indwelling ureteral stent removal following primary or salvage pyeloplasty in US adult patients is affected by demographic and perioperative factors: Results from a large population-based cohort analysis
Authors: F. Del Giudice, V. Asero, S. Salcicci, S. Li, F. Belladelli, A. Sciarra, C.M. Scornajenghi, E. Bologna, E. De Berardinis, S. Basran, B.I. Chung
Journal: European Urology (2023)
Investigating the role of the prostate multiparametric magnetic resonance imaging sequences quality on biopsies’ outcomes
Authors: A.L. Pastore, M. Rengo, P.P. Suraci, A. Fuschi, Y. Al Salhi, A. Martoccia, S. Scalzo, O.A. Rera, F.M. Valenzi, A. Antonioni, M.B. Sequi, D. Graziani, A. Sciarra, F. Del Giudice, C. Leonardo, G. Franco, C. De Nunzio, A. Tubaro, P. Capodiferro, A. Carbone
Journal: European Urology (2023)
Evaluation of miRNA-371a-3p (miR371a) assay to predict final pathohistology in patients undergoing primary nerve-sparing Retroperitoneal Lymphadenectomy (nsRPLND) for stage IIA/B seminomas and non-seminomas
Authors: F. Seelemeyer, D. Pfister, R. Pappesch, S. Merkelbach-Bruse, C. Stammel, P. Paffenholz, A. Heidenreich
Journal: European Urology (2023)
Is there a preferential lymph node metastasis pathway in prostate cancer according to the site of the index lesion at multiparametric MRI? A topographic mapping study
Authors: F. Pellegrino, G. Gandaglia, A. Stabile, V. Cucchiara, E. Mazzone, S. Scuderi, F. Barletta, D. Robesti, A. Pellegrino, L. Quarta, P. Zaurito, N. Tenace, G. Brembilla, R. Lucianò, F. De Cobelli, F. Montorsi, A. Briganti
Journal: European Urology (2023)
Practical problems and responses for SARS-CoV-2 laboratory testing during the COVID-19 pandemic
Authors: Julian W. Tang, Meik Dilcher, Paul W. Bird, Jen Kok, Chun Kiat Lee, Hidekazu Nishimura, Lynette Oon, Ginna Alston, Dominic E. Dwyer, Christopher W. Holmes, Lance C. Jennings
Journal: Clinical Microbiology and Infection (2023)
SampleQC: robust multivariate, multi-cell type, multi-sample quality control for single-cell data
Authors: Will Macnair, Mark Robinson
Journal: Genome biology (2023)

Abstract Quality control (QC) is a critical component of single-cell RNA-seq (scRNA-seq) processing pipelines. Current approaches to QC implicitly assume that datasets are comprised of one cell type, potentially resulting in biased exclusion of rare cell types. We introduce , which robustly fits a Gaussian mixture model across multiple samples, improves sensitivity, and reduces bias compared to current approaches. We show via simulations that is less susceptible to exclusion of rarer cell types. We also demonstrate on a complex real dataset (867k cells over 172 samples). is general, is implemented in R, and could be applied to other data types.
HTLV seroprevalence in people using HIV pre-exposure prophylaxis in England
Authors: Daniel Bradshaw, Arham Khawar, Poorvi Patel, Jennifer Tosswill, Colin Brown, Dana Ogaz, Emily Mason, Roeann Osman, Holly Mitchell, Olamide Dosekun, Borja Mora Peris, Graham Pickard, Michael Rayment, Rachael Jones, Mark Hopkins, Andy Williams, Margaret Kingston, Nicholas Machin, Yusri Taha, Sarah Duncan, Neil Turner, Noel Gill, Nick Andrews, Mohammad Raza, Simon Tazzyman, Achyuta Nori, Emma Cunningham, Graham P Taylor
Journal: Journal of Infection (2023)

<h2>Summary</h2><h3>Objectives</h3> HTLV-1 is predominantly a sexually-transmitted infection but testing is not mentioned in HIV-PrEP guidelines. We ascertained HTLV-1/HTLV-2 seroprevalence amongst HIV-PrEP users in England. <h3>Methods</h3> An unlinked anonymous seroprevalence study. <h3>Results</h3> Amongst 2015 HIV-PrEP users, 95% were men, 76% of white ethnicity and 83% had been born in Europe. There were no HTLV-1/HTLV-2 seropositive cases (95% confidence interval 0% – 0.18%). <h3>Conclusions</h3> There were no HTLV positive cases, likely reflecting the demographic of mostly white and European-born individuals. Similar studies are needed worldwide to inform public health recommendations for HIV-PrEP using populations, particularly in HTLV-endemic settings.
Efficacy of downtitration or treatment withdrawal compared with continuous dosing after successful treatment with baricitinib in patients with moderate-to-severe atopic dermatitis in a randomized substudy from the long-term extension study BREEZE-AD3
Authors: Kristian Reich, Eric Simpson, Andreas Wollenberg, Robert Bissonnette, Masatoshi Abe, Tracy Cardillo, Jonathan Janes, Luna Sun, Sherry Chen, Jonathan I Silverberg
Journal: British Journal of Dermatology (2022)

Baricitinib, an oral, selective Janus kinase 1/2 inhibitor, demonstrated long-term efficacy in moderate-to-severe atopic dermatitis in an ongoing double-blind, phase III, long-term extension study, BREEZE-AD3 (NCT03334435).To evaluate the efficacy and safety of downtitration and treatment withdrawal in a substudy of BREEZE-AD3.The substudy included patients (N = 526) treated with baricitinib 4 mg or 2 mg at entry into BREEZE-AD3 who achieved a validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD®) scale score of 0 (clear), 1 (almost clear) or 2 (mild) at week 52. Patients treated with baricitinib 4 mg were rerandomized to baricitinib 4 mg (continuous dosing), baricitinib 2 mg (downtitration) or placebo (treatment withdrawal, 4-mg cohort), and patients treated with baricitinib 2 mg were rerandomized to baricitinib 2 mg (continuous dosing), baricitinib 1 mg (downtitration), or placebo (treatment withdrawal, 2-mg cohort). After 16 weeks, we assessed the proportion of patients with vIGA-AD® 0/1, vIGA-AD® 0/1/2, vIGA-AD® ≥ 3 (loss of response; criterion to readminister the original baricitinib dose) and for patients who were readministered the original baricitinib dose, we assessed the proportion of patients who recaptured vIGA-AD® 0/1/2 within 16 weeks of treatment readministration (patients in the continuous dosing maintained the same dose).For the continuous dosing, downtitration, and treatment withdrawal groups 51%, 45% and 30% of patients in the 4-mg cohort achieved vIGA-AD® 0/1 and 87%, 61% and 50% of patients achieved vIGA-AD® 0/1/2, respectively. For the 2-mg cohort, the respective proportions of patients were 48%, 42% and 25% for vIGA-AD® 0/1 and 92%, 71% and 45% for vIGA-AD® 0/1/2. The respective proportions of patients with vIGA-AD® ≥ 3 were 39%, 49% and 56% in the 4-mg cohort and 41%, 41% and 64% in the 2-mg cohort. Of those who were readministered the original baricitinib dose, the proportions of patients who recaptured vIGA-AD® 0/1/2 among the continuous dosing, downtitration, and treatment withdrawal groups were 80%, 85% and 88% in the 4-mg cohort and 90%, 56% and 86% in the 2-mg cohort, respectively.Baricitinib allows flexibility for patients to downtitrate or stop treatment. For patients who downtitrated treatment, the majority maintained efficacy through 16 weeks. Most patients who lost efficacy with downtitration or treatment withdrawal achieved clinically relevant efficacy upon readministration of their original dose.
Body Extension by Using Two Mobile Manipulators
Authors: Yusuke Hirao, Weiwei Wan, Dimitrios Kanoulas, Kensuke Harada
Journal: Cyborg and Bionic Systems (2023)

This paper presents a remotely operated robotic system that includes two mobile manipulators to extend the functional capabilities of a human body. Compared with previous tele-operation or robotic body extension systems, using two mobile manipulators helps with enlarging the workspace and allowing manipulation of large or long objects. The system comprises a joystick for controlling the mobile base and robotic gripper, and a motion capture system for controlling the arm poses. They together enable tele-operated dual-arm and large-space manipulation. In the experiments, a human tele-operator controls the two mobile robots to perform tasks such as handover, long object manipulation, and cooperative manipulation. The results demonstrated the effectiveness of the proposed system, resulting in extending the human body to a large space while keeping the benefits of having two limbs.
Assessing overdiagnosis of fecal immunological test screening for colorectal cancer with a digital twin approach
Authors: Ting-Yu Lin, Sherry Yueh-Hsia Chiu, Ling-Chun Liao, Sam Li-Sheng Chen, Han-Mo Chiu, Tony Hsiu-Hsi Chen
Journal: npj Digital Medicine (2023)

Abstract Evaluating the magnitude of overdiagnosis associated with stool-based service screening for colorectal cancer (CRC) beyond a randomized controlled trial is often intractable and understudied. We aim to estimate the proportion of overdiagnosis in population-based service screening programs for CRC with the fecal immunochemical test (FIT). The natural process of overdiagnosis-embedded disease was first built up to learn transition parameters that quantify the pathway of non-progressive and progressive screen-detected cases calibrated with sensitivity, while also taking competing mortality into account. The Markov algorithms were then developed for estimating these transition parameters based on Taiwan FIT service CRC screening data on 5,417,699 residents aged 50–69 years from 2004 to 2014. Following the digital twin design with the parallel universe structure for emulating the randomized controlled trial, the screened twin, mirroring the control group without screening, was virtually recreated by the application of the above-mentioned trained parameters to predict CRC cases containing overdiagnosis. The ratio of the predicted CRCs derived from the screened twin to the observed CRCs of the control group minus 1 was imputed to measure the extent of overdiagnosis. The extent of overdiagnosis for invasive CRCs resulting from FIT screening is 4.16% (95% CI: 2.61–5.78%). The corresponding figure is increased to 9.90% (95% CI: 8.41–11.42%) for including high grade dysplasia (HGD) and further inflated to 15.83% (95% CI: 15.23–16.46%) when the removal adenoma is considered. The modest proportion of overdiagnosis modelled by the digital twin method, dispensing with the randomized controlled trial design, suggests the harm done to population-based FIT service screening is negligible.
Evidence from ClinicalTrials.gov on the growth of Digital Health Technologies in neurology trials
Authors: Lars Masanneck, Pauline Gieseler, William J. Gordon, Sven G. Meuth, Ariel D. Stern
Journal: npj Digital Medicine (2023)

Digital Health Technologies (DHTs) such as connected sensors offer particular promise for improving data collection and patient empowerment in neurology research and care. This study analyzed the recent evolution of the use of DHTs in trials registered on ClinicalTrials.gov for four chronic neurological disorders: epilepsy, multiple sclerosis, Alzheimer's, and Parkinson's disease. We document growth in the collection of both more established digital measures (e.g., motor function) and more novel digital measures (e.g., speech) over recent years, highlighting contexts of use and key trends.